• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » NEOMED Institute aims to renew biopharmaceutical research in Québec

NEOMED Institute aims to renew biopharmaceutical research in Québec

November 27, 2012
CenterWatch Staff

AstraZeneca Canada and Pfizer Canada are forming a partnership with the Québec government to create the NEOMED Institute, a new kind of life sciences research center. A total of $100 million will be invested to establish and support the research center over five years.

The NEOMED Institute will act as a catalyst in two ways: by creating a bridge between academic research and life sciences companies, and by providing an environment to create synergies between the main biotech industry players. The nonprofit research hub will seek to bring key stakeholders in the R&D chain—including researchers, universities, biotech and pharma companies and venture capital funds—under the same roof, working together in an open, collaborative environment. More than 100 highly qualified employees are expected to work there at full capacity.

AstraZeneca Canada is donating $35 million to the NEOMED Institute, including land, the neuroscience basic research facility and laboratory equipment. It also includes the donation of intellectual property to three AstraZeneca pain molecules and projects, as well as $5 million to support the activities of the institute. Pfizer Canada is providing a financial contribution of approximately $3.5 million, and the Québec government is contributing $28 million.

Based on a model that involves sharing knowledge, expertise and resources, the NEOMED Institute aims to strengthen the life sciences sector in Québec by helping to stimulate research and collaboration, and accelerate and facilitate the transition from academic research to the development of new drugs. It will also seek to attract investment by showcasing the results of local research to international investors.

"The cost of discovering new drugs keeps rising and pharmaceutical companies need to adapt," said Max Fehlmann, new president and CEO of the institute, which will be located in the former AstraZeneca building in the Saint-Laurent borough's technology park. "The NEOMED Institute, acting as a competitive actor in the drug development sector, will allow Québec's scientists to make the bridge between academic innovations and commercial opportunities in a better way."

Elaine Campbell, president of AstraZeneca Canada, said, "Today's announcement is a strong testament to AstraZeneca's commitment to biopharmaceutical research and development in Quebec and Canada. Through the creation of the NEOMED Institute, we're proud to be working in collaboration with our partners to advance drug discovery and bridge the innovation gap through to successful commercialization."

"We are excited by NEOMED because it exemplifies the type of partnership activity that is needed in our new R&D model,” added John Helou, president of Pfizer Canada. “NEOMED complements our long-time Canadian R&D investment strategy, which has been focused on innovative partnerships."

NEOMED is a response to the changing pharma R&D business model: in view of the considerable gap between basic research and later-stage drug development, it seeks to create a bridge, providing expertise and funding for academic labs and early biotechs and assisting them in bringing emerging therapeutic approaches to the stage of human proof of concept. These de-risked projects then will have gained significant value for NEOMED's downstream partners.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing